paliwizumab - Meklēšanas rezultāti

Namībija - angļu - Namibia Medicines Regulatory Council

synagis 100

abbvie (pty) ltd - palivizumab - injection - each 1ml vial when reconstituted contains palivizumab 100 mg

Namībija - angļu - Namibia Medicines Regulatory Council

synagis

abbvie (pty) ltd - palivizumab - solution for injection - each ml contains: palivizumab 10,00 0mg

Namībija - angļu - Namibia Medicines Regulatory Council

lucentis

novartis south africa (pty) ltd - ranibizumab - solution for injection - each 1,0 ml solution contains ranibizumab 10,0 mg

Izraēla - angļu - Ministry of Health

abbosynagis 100 mg

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Izraēla - angļu - Ministry of Health

abbosynagis 50 mg

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.